Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.36 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.33 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.33 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.33 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.33 |
| ▸ | IDO1 | P14902 | 1/20 | 0.33 |
| ▸ | BACE1 | P56817 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | MPO | P05164 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2675279 | 0.90 | ELANE (0.38) | NPSR1TAAR1RIPK1MPO | |
| SCHEMBL30039264 | 0.86 | CYP4F2 (0.36) | RIPK1IDO1BACE1HTT | |
| SCHEMBL6943654 | 0.86 | CYP4F2 (0.36) | RIPK1IDO1BACE1HTT | |
| SCHEMBL3255650 | 0.86 | TAAR1 (0.31) | TAAR1IDO1 | |
| SCHEMBL19812300 | 0.85 | TAAR1 (0.37) | NPSR1TAAR1RIPK1ALDH1A1SIGMAR1 | |
| SCHEMBL8700617 | 0.85 | ADRA2A (0.41) | NPSR1TAAR1RIPK1 | |
| SCHEMBL13442234 | 0.84 | TBXA2R (0.33) | SIGMAR1 | |
| SCHEMBL388941 | 0.83 | TAAR1 (0.56) | TAAR1 | |
| SCHEMBL9621391 | 0.82 | TAAR1 (0.40) | TAAR1MTNR1AMTNR1BALDH1A1SIGMAR1 | |
| SCHEMBL16113242 | 0.82 | TAAR1 (0.35) | NPSR1TAAR1RIPK1ALDH1A1SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9663536-B2 | Inhibitors of human immunodeficiency virus replication | VIIV Healthcare UK (No.5) Limited (GB) | 2017-05-30 | — | — | US | disclosed |
| US-9663536-B2 | Inhibitors of human immunodeficiency virus replication | VIIV Healthcare UK (No.5) Limited (GB) | 2017-05-30 | — | — | US | disclosed |
| EP-2970274-B1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | VIIV HEALTHCARE UK (NO 5) LTD (GB) | 2017-03-01 | — | — | EP | disclosed |
| EP-2970301-B1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | VIIV HEALTHCARE UK (NO 5) LTD (GB) | 2017-01-11 | — | — | EP | disclosed |
| US-9540393-B2 | Inhibitors of human immunodeficiency virus replication | VIIV Healthcare UK (No.5) Limited (GB) | 2017-01-10 | — | — | US | disclosed |
| US-9540393-B2 | Inhibitors of human immunodeficiency virus replication | VIIV Healthcare UK (No.5) Limited (GB) | 2017-01-10 | — | — | US | disclosed |
| US-9527842-B2 | Inhibitors of human immunodeficiency virus replication | VIIV Healthcare UK (No.5) Limited (GB) | 2016-12-27 | — | — | US | disclosed |
| US-9527842-B2 | Inhibitors of human immunodeficiency virus replication | VIIV Healthcare UK (No.5) Limited (GB) | 2016-12-27 | — | — | US | disclosed |
| US-20160039844-A1 | Inhibitors of Human Immunodeficiency Virus Replication | VIIV HEALTHCARE UK (NO. 5) LIMITED (GB) | 2016-02-11 | — | — | US | disclosed |
| US-20160039844-A1 | Inhibitors of Human Immunodeficiency Virus Replication | VIIV HEALTHCARE UK (NO. 5) LIMITED (GB) | 2016-02-11 | — | — | US | disclosed |
| US-20160002263-A1 | Inhibitors of Human Immunodeficiency Virus Replication | VIIV HEALTHCARE UK (NO. 5) LIMITED (GB) | 2016-01-07 | — | — | US | disclosed |
| WO-2014164428-A1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-10-09 | — | — | WO | disclosed |
| WO-2014159076-A1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-10-02 | — | — | WO | disclosed |
| WO-2014159959-A1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-10-02 | — | — | WO | disclosed |
| EP-2776038-A1 | ACC INHIBITORS AND USES THEREOF | Nimbus Apollo Inc. (US) | 2014-09-17 | — | — | EP | disclosed |
| WO-2013071169-A1 | ACC INHIBITORS AND USES THEREOF | Nimbus Apollo, Inc. (US) | 2013-05-16 | — | — | WO | disclosed |
| EP-0904284-A1 | 6-SUBSTITUTED AMINO-4-OXA-1-AZABICYCLO (3,2,0) HEPTAN-7-ONE DERIVATIVES AS CYSTEINE PROTEASE INHIBITORS | SYNPHAR LABORATORIES INC. (CA) | 1999-03-31 | — | — | EP | disclosed |
| WO-1997038008-A1 | 6-SUBSTITUTED AMINO-4-OXA-1-AZABICYCLO[3,2,0] HEPTAN-7-ONE DERIV ATIVES AS CYSTEINE PROTEASE INHIBITORS | SYNPHAR LABORATORIES INC. (US) | 1997-10-16 | — | — | WO | disclosed |
| EP-0307106-B1 | P- OR M-TERT BUTOXYPHENETHYL ALCOHOL AND PROCESS FOR PREPARING THE SAME | HOKKO CHEMICAL INDUSTRY CO., LTD (JP) | 1992-01-15 | — | — | EP | disclosed |
| EP-0307106-A1 | P- or m-tert butoxyphenethyl alcohol and process for preparing the same | HOKKO CHEMICAL INDUSTRY CO., LTD (JP) | 1989-03-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160039844-A1 | Inhibitors of Human Immunodeficiency Virus Replication | EIF2AK2, RTF2, MAVS | NPSR1 4624/4885TAAR1 4796/4885RIPK1 1631/4885 |
| US-20160002263-A1 | Inhibitors of Human Immunodeficiency Virus Replication | EIF2AK2, EFTUD2, SARS1 | NPSR1 4825/4885TAAR1 4882/4885RIPK1 1183/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.